BUPRENORPHINE
Body System:
Manner of administration:Transdermal
Restriction
Indication: Severe disabling pain
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 2 | Max qty units: 4 | # of repeats: 0 | DPMQ: $46.44 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
|
|
|||||
|
|
|||||
|
|
|||||
|
|
|||||
Body System:
Manner of administration:Transdermal
Restriction (Streamlined authority code: 10755)
Indication: Chronic severe pain
Treatment phase: Initial PBS treatment after 1 June 2020 where patient has been treated with opioids
for less than 12 months
Restriction (Streamlined authority code: 10748)
Indication: Chronic severe pain
Treatment phase: Initial PBS treatment after 1 June 2020 where patient has been treated with opioids
for more than 12 months
Restriction (Streamlined authority code: 10752)
Indication: Chronic severe pain
Treatment phase: Continuing PBS treatment after 1 June 2020
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 2 | # of repeats: 0 | DPMQ: $32.86 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
|
|
|||||
|
|
|||||
|
|
|||||
|
|
|||||